Why the study?
How lipotoxicity impairs cardiac function and diabetes mellitus sparks clinical syndromes in diabetic cardiomyopathy remains unclear.
This review provides insights into the metabolic drivers of diabetic cardiomyopathy, specifically lipotoxicity, and highlights emerging therapeutic strategies.
Diabetes mellitus (DM) ignites a global epidemic, with cardiovascular complications claiming most lives among affected patients. Diabetic cardiomyopathy (DCM), a distinct cardiac dysfunction triggered by DM independent of coronary artery disease or hypertension, threatens those with type 1 or type 2 DM, often leading to heart failure. In type 2 DM (T2DM), metabolic disruptions drive cardiac lipotoxicity. Yet, how lipotoxicity impairs function and DM sparks clinical syndromes remains unclear. This review unveils how DM rewires myocardial metabolism-favoring lipids over glucose-and probes emerging therapies, spotlighting clinical challenges at a vital research frontier.
No takes yet. Share an insight, caveat, or question.
Guan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: